These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15285873)

  • 1. Gold standard or wrong standard?
    Oldham R; Dillman R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):271-2. PubMed ID: 15285873
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate for melanoma: will a new target be revealed?
    Grossman D
    J Invest Dermatol; 2004 Dec; 123(6):xi-xiii. PubMed ID: 15610499
    [No Abstract]   [Full Text] [Related]  

  • 3. New agents in cancer clinical trials.
    Adams J; Elliott PJ
    Oncogene; 2000 Dec; 19(56):6687-92. PubMed ID: 11426656
    [No Abstract]   [Full Text] [Related]  

  • 4. Researchers optimistic about sea change in cancer treatment.
    Stephenson J
    JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
    [No Abstract]   [Full Text] [Related]  

  • 5. A new era in cancer therapeutics?
    Westwell AD
    Drug Discov Today; 2003 Jan; 8(2):64-5. PubMed ID: 12565007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib: high dose versus standard dose.
    Jabbour E
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):812-4. PubMed ID: 20332752
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
    Sausville EA
    Lancet; 2003 Apr; 361(9367):1400-1. PubMed ID: 12727387
    [No Abstract]   [Full Text] [Related]  

  • 8. [Optimizing current drugs].
    Blay JY
    Ann Pharm Fr; 2005 Jan; 63(1):17-24. PubMed ID: 15803096
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib Changed Everything.
    Longo DL
    N Engl J Med; 2017 Mar; 376(10):982-983. PubMed ID: 28273011
    [No Abstract]   [Full Text] [Related]  

  • 10. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 11. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
    Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
    J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
    [No Abstract]   [Full Text] [Related]  

  • 13. India's patent case victory rattles Big Pharma.
    Chatterjee P
    Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911
    [No Abstract]   [Full Text] [Related]  

  • 14. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?
    Carnevale-Schianca F; Gallo S; Rota-Scalabrini D; Sangiolo D; Fizzotti M; Caravelli D; Capaldi A; Anselmetti G; Palesandro E; D'Ambrosio L; Coha V; Obert R; Aglietta M; Grignani G
    J Clin Oncol; 2011 Aug; 29(24):e691-3. PubMed ID: 21709191
    [No Abstract]   [Full Text] [Related]  

  • 15. Growth-factor inhibition as therapy for Kaposi's sarcoma.
    Senior K
    Lancet Oncol; 2005 Jan; 6(1):7. PubMed ID: 15672489
    [No Abstract]   [Full Text] [Related]  

  • 16. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
    Malhotra KP; Sharma CB; Jain J; Grover RK
    J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
    [No Abstract]   [Full Text] [Related]  

  • 17. Why is cancer drug discovery so difficult?
    Kamb A; Wee S; Lengauer C
    Nat Rev Drug Discov; 2007 Feb; 6(2):115-20. PubMed ID: 17159925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desmoid-type fibromatosis.
    Bertucci F; Gonçalves A; Viens P; Monges G; Dubreuil P
    J Neurosurg; 2007 Aug; 107(2):473-5; author reply 475. PubMed ID: 17695408
    [No Abstract]   [Full Text] [Related]  

  • 19. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
    Botella-Estrada R; Soriano V; Rubio L; Nagore E
    Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
    [No Abstract]   [Full Text] [Related]  

  • 20. The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.
    Sleijfer S; Wagner AJ
    J Clin Oncol; 2012 Mar; 30(9):896-8. PubMed ID: 22331936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.